CAR-γδT cells for refractory autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of autoimmune disease that has not responded to standard treatments (like steroids, immune-suppressing drugs, or biologics) for at least 6 months, or it came back after getting better.
- You are currently on a stable dose of at least one standard treatment (like steroids, hydroxychloroquine, or other immune-suppressing drugs).
- You have not had CAR-T cell therapy before.
- You are willing to use effective birth control during the study and for 6 months after (if you or your partner could become pregnant).
- You are able to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a new type of 'universal' CAR-T cell therapy (made from donor cells) combined with immune-suppressing drugs for people with severe autoimmune diseases that haven't responded to standard treatments. The goal is to see if this approach can control the immune system and reduce disease activity.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.